🏛️ Verified NIH Record • Updated 2026-04-09
Study of Sacituzumab Govitecan in Participants With Metastatic Solid Tumors (NCT03964727)
A Phase 2 Open-Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Gilead Sciences
🩺 Plain-English Summary (8th-Grade Level)
The goal of this clinical study is to learn more about the study drug, sacituzumab govitecan-hziy, in participants with metastatic (cancer that has spread) solid tumors.
Who can join: Review the eligibility criteria below.
Location: Alaska Oncology & Hematology, LLC — Anchorage, Alaska
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (65 Sites)
Showing the first 25 of 65 sites.
- Alaska Oncology & Hematology, LLC — Anchorage, Alaska
- USOR - Arizona Oncology - Glendale - Saguaro Cancer Center — Glendale, Arizona
- Arizona Oncology Associates PC-HAL — Goodyear, Arizona
- Highlands Oncology Group — Springdale, Arkansas
- UCLA Hematology/Oncology — Los Angeles, California
- TRIO-US Central Administration — Whittier, California
- University of Colorado Hospital - Anschutz Cancer Pavilion — Aurora, Colorado
- Smilow Cancer Hospital at Yale — New Haven, Connecticut
- SIU School of Medicine, Simmons Cancer Institute at SIU — Springfield, Illinois
- PathGroup Labs, LLC — Fort Wayne, Indiana
- Parkview Research Center — Fort Wayne, Indiana
- University of Kentucky Medical Center — Lexington, Kentucky
- Christus Highland Cancer Treatment Center — Shreveport, Louisiana
- University of Michigan Rogel Cancer Center — Ann Arbor, Michigan
- Karmanos Cancer Institute — Detroit, Michigan
- North Mississippi Medical Center - Hematology and Oncology - Tupelo — Tupelo, Mississippi
- Washington University School of Medicine - Siteman Cancer Center — St Louis, Missouri
- David C. Pratt Center — St Louis, Missouri
- Comprehensive Cancer of Nevada — Las Vegas, Nevada
- New York Oncology Hematology - Albany Medical Center — Albany, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medicine - Upper East Side — New York, New York
- Montefiore Medical Center — The Bronx, New York
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Willamette Valley Cancer Institute and Research Center - Eugene — Eugene, Oregon
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Metastatic Solid Tumor
- A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors — Orlando, Florida
- Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS — Coral Gables, Florida
- Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) — Baltimore, Maryland
- TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) — Los Angeles, California
- QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors — El Segundo, California
Explore by condition: All Metastatic Solid Tumor clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.